Merck Stock News

Merck (MRK) announced that the FDA issued it a Complete Response Letter ((CRL)) regarding its New Drug Application ((NDA)) for gefapixant, an experimental therapy for refractory

Researchers Worry COVID Will Quickly Develop Resistance To New Pills From Pfizer And Merck If it wasn''t already bad enough that several experts have warned that US regulators are overlooking safety risks associated with the new generation of COVID therapeutic pills from Pfizer and Merck, researchers and regulators are also apparently worried that they might not even work - at least, not for long. According to a report in WSJ, researchers and academics are already taking steps to keep an eye out for signs that COVID is evolving in response to exposure to pills like Paxlovid and Molnupiravir. The hope is that the pills will save more lives, especially now that the vaccines and boosters have been surprisingly ineffective at prevent transmission and infection with the virus. "We know this is likely to happen at some point, so we need to beat it to the punch and nip it in the bud before it gets out of hand and starts to take over," said Katherine Seley-Radtke, a medicinal-chemistry professor at the University of Maryland, Baltimore County, whose lab is studying antiviral combination therapies.

Pfizer (PFE) and Merck (MRK), the developers of the first oral medications for COVID-19 in the U.S., are advancing combination studies for their antiviral therapies as experts flag the

Bloomberg reported that Merck & Co Inc (NYSE: MRK ) has won a long-running legal battle to force its insurer to cover the costs of damages caused by the NotPetya'' ransomware'' attacks. Merck and its insurers have been battling over $1.4 billion in losses from the attack in 2017 after filing a lawsuit seeking to reclaim financial losses from the "NotPetya" incident. Many companies, including Merck, found their insurer refusing to pay because of an exclusion in their policy for "acts of war." A New Jersey superior court judge has now ruled that Full story available on Benzinga.com

A U.N.-backed group says it has signed agreements with more than two dozen generic drug makers to produce versions of Mercks coronavirus pill to supply 105 developing countries

Phase 3 data from the KEYNOTE-394 data of Merck Keytruda (pembrolizumab) showed improvement in overall survival, progression-free survival, and objective response rate.

New York, NY, and Tel Aviv, ISRAEL January 18, 2022 - Todos Medical, Ltd. (OTCQB: TOMDF ) , a comprehensive medical diagnostics and related solutions company, today released videos of recent interviews with Fox Business, Black New Channel and NewsMax where CEO Gerald Commissiong discusses strategies for improving the current COVID testing paradigm in the United States and how this interplay with the effectiveness of emerging oral antiviral treatments, including Pfizers (NYSE: PFE ) Paxlovid® and Mercks (NYSE: MRK ) Mulnupiravir® that both received Emergency Use Authorization (EUA) from the US Food & Drug Administration in December 2021, as well as Todos investigational oral all natural botanical drug candidate Tollovir that will be reading out on Phase 2 clinical trial data for the treatment of hospitalized (severe/critical) COVID-19 patients on January 27 th , 2022. Links to the interviews can be found below. Fox Business on 1/11/22: https://www.youtube.com/watch?v=kbJTx-aiP4Q NewsMax on 1/15/22: https://www.youtube.com/watch?v=F3w6S0JYMfM Black New Channel on 1/17/22: https://www.youtube.com/watch?v=5TIFBsGV8pU As we raise the profile of what we are doing at Todos to help with the COVID-19 pandemic, we are committed to taking a non-political position, speaking with both Democrats and Republicans, and staying squarely rooted in making recommendations based on the best currently available data to promote the best use of the FDA-authorized tools at the publics disposal to help guide the population back towards normal life while the pandemic continues forward, said Gerald E.

Merck and partner privately held Ridgeback Biotherapeutics said Tuesday they have won a supply agreement from the United Nations Children''s Fund, or Unicef, to provide it with up to 3 million doses of their COVID-19 antiviral molnupiravir in the first half of 2022. The doses will be distributed in more than 100 low and middle-income countries following regulatory authorizations. The treatment has already been authorized in more than 10 countries, including the U.S., UK, Japan and Taiwan. Merck shares were not yet active premarket, but have gained 2.4% in the last 12 months, while the S&P 500 has gained 24%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Last month, the FDA approved both the Pfizer and Merck pills that studies show cut the chances of severe disease and death.

Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cancer is the 2nd-leading cause of death in the United States, responsible for 1 in 4 deaths nationwide each year. With 3.8 million cases as of January 2021 and 250,000 new diagnoses each year, breast cancer is by far the most rapidly spreading type of cancer among women. Its also the 2nd most fatal, causing roughly 42,000 deaths per year. As cases continue to rise, the nations leading cancer researchers are working urgently to improve survival rates among breast cancer patients, especially those with later-stage metastatic breast cancer who have an abysmal 22% chance of surviving up to 5 years after diagnosis. Oncolytics Biotech Inc. (NASDAQ: ONCY ) hopes to change that with its lead drug candidate, pelareorep . With multiple clinical trials completed and underway, the biotechs immunotherapy drug candidate seems to offer the hope patients with metastatic breast cancer need, especially when combined with other leading treatments on the market today.

LONDON, Jan. 12, 2022 (GLOBE NEWSWIRE) -- According to The Business Research Company''s research report on the animal medicine market, the production of medicated feed additives is a major trend in the animal medicine market. Medicated feed additives in general help maintain animal health and promote growth and feed efficiency. They include vitamins, amino acids, fatty acids, pharmaceuticals, minerals, growth hormones and fungus. Animal medicines manufacturers have started increasingly producing medicated feed additives to improve efficiencies of production. For instance, in January 2020, Kemin Industries, a US-based ingredient manufacturer, launched VANNIX C4, a novel phytogenic feed additive for poultry gut health. VANNIX C4 is a probiotic feed additive formulation of gut-health-fortifying ingredients to minimize the impact of enteric challenges on poultry performance. The global animal medicine market size grew from $32.7 billion in 2020 to $37.88 billion in 2021 at a compound annual growth rate (CAGR) of 15.8% .

IMV (IMV) said the first patient was dosed in a phase 2B trial called VITALIZE, evaluating its lead compound maveropepimut-S (MVP-S), in combination with Merck & Co

DUBLIN , Jan. 12, 2022 /PRNewswire/ -- The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021" report has been added to ResearchAndMarkets.com''s offering. The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2021 report provides comprehensive access to available deals and contract documents for over 2,900 clinical stage deals. The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner''s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ: ALGS ) a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has expanded its ongoing collaboration agreement with Merck to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis (NASH). "We believe that one of our strengths as a company is our technical know-how in several areas of oligonucleotide research and development," said Lawrence Blatt, Ph.D., MBA, Chairman and Chief Executive Officer of Aligos. "We are pleased to broaden our collaboration where we may be able to contribute to creating effective, targeted therapies for NASH together with Merck." Under the original agreement, Merck and Aligos committed to applying Aligos'' oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a certain undisclosed non-alcoholic steatohepatitis (NASH) target and up to one additional target of interest in the cardiometabolic/fibrosis space.